ORIC PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax
ORIC PHARMACEUTICALS, INC. (ORIC) had Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax of $3.00 thousand as of 2021-06-30, per its 10-Q filed 2021-08-10.
Discontinued › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2021-08-10
- 2021-06-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $3.00K.
- 2021-03-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $17.00K.
| Period end | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2021-06-30 | $3.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $17.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |